Erratum: Endogenous Plasma Erythropoietin, Cardiovascular Mortality and All-Cause Mortality in Renal Transplant Recipients: American Journal of Transplantation (2012) 12 (485-491) DOI: 10.1111/j.1600-6143.2011.03825.x);Endogenous plasma erythropoietin, cardiovascular mortality and all-cause mortality in renal transplant recipients

American Journal of Transplantation

Volumn 12, Issue 2, 2012, Pages 485-491

  Sinkeler, S J ^a   Zelle, D M ^a   Homan Van Der Heide, J J ^b   Gans, R O B ^b   Navis, G ^a   Bakker, S J L ^b  

^a Department of Internal Medicine   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cardiovascular mortality; erythropoietin; renal transplant recipients; survival

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CYCLOSPORIN; DIURETIC AGENT; ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ANGIOGENESIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CREATININE CLEARANCE; FEMALE; FOLLOW UP; FRAMINGHAM RISK SCORE; GENDER; GRAFT RECIPIENT; HORMONE BLOOD LEVEL; HUMAN; HYPOXIA; INFLAMMATION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; MEDICAL HISTORY; MORTALITY; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 84856478839     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.04025.x     Document Type: Erratum

References (20)

1. Oterdoom LH, de Vries AP, van Ree RM, et al,. N-terminal pro-B-type natriuretic peptide and mortality in renal transplant recipients versus the general population. Transplantation 2009; 87: 1562-1570.
2. Vanrenterghem YF, Claes K, Montagnino G, et al,. Risk factors for cardiovascular events after successful renal transplantation. Transplantation 2008; 85: 209-216. (Pubitemid 351222383)
3. Molnar MZ, Czira M, Ambrus C, et al,. Anemia is associated with mortality in kidney-transplanted patients-a prospective cohort study. Am J Transplant 2007; 7: 818-824. (Pubitemid 46481205)
4. Pfeffer MA, Burdmann EA, Chen CY, et al,. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032.
5. Singh AK, Szczech L, Tang KL, et al,. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098. (Pubitemid 44749317)
6. van der Meer P, Voors AA, Lipsic E, Smilde TD, van Gilst WH, van Veldhuisen DJ,. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll Cardiol 2004; 44: 63-67. (Pubitemid 38968458)
7. Wagner M, Alam A, Zimmermann J, et al,. Endogenous erythropoietin and the association with inflammation and mortality in diabetic chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 1573-1579.
8. de Vries AP, Bakker SJ, van Son WJ, et al,. Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally. Am J Transplant 2004; 4: 1675-1683. (Pubitemid 39312303)
9. World Health Organization. Iron-Deficiency Anemia: Assessment, Prevention, and Control. Geneva, Switzerland: Author; 2001.
10. van Ree RM, de Vries AP, Oterdoom LH, et al,. Abdominal obesity and smoking are important determinants of C-reactive protein in renal transplant recipients. Nephrol Dial Transplant 2005; 20: 2524-2531. (Pubitemid 41548882)
11. Ershler WB, Sheng S, McKelvey J, et al,. Serum erythropoietin and aging: A longitudinal analysis. J Am Geriatr Soc 2005; 53: 1360-1365. (Pubitemid 41613396)
12. Ranjbaran H, Sokol SI, Gallo A, et al,. An inflammatory pathway of IFN-gamma production in coronary atherosclerosis. J Immunol 2007; 178: 592-604. (Pubitemid 46033643)
13. Virmani R, Kolodgie FD, Burke AP, et al,. Atherosclerotic plaque progression and vulnerability to rupture: Angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol 2005; 25: 2054-2061. (Pubitemid 41416300)
14. Watanabe D, Suzuma K, Matsui S, et al,. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 2005; 353: 782-792. (Pubitemid 41215487)
15. Mak RH,. Metabolic effects of erythropoietin in patients on peritoneal dialysis. Pediatr Nephrol 1998; 12: 660-665. (Pubitemid 28472924)
16. Gossmann J, Burkhardt R, Harder S, et al,. Angiotensin II infusion increases plasma erythropoietin levels via an angiotensin II type 1 receptor-dependent pathway. Kidney Int 2001; 60: 83-86. (Pubitemid 32587542)
17. Slagman MC, Sinkeler SJ, Hemmelder MH, et al,. Erythropoietin is reduced by combination of diuretic therapy and RAAS blockade in proteinuric renal patients with preserved renal function. Nephrol Dial Transplant 2010; 25: 3256-3260.
18. Dzau VJ., Theodore Cooper Lecture. Tissue angiotensin and pathobiology of vascular disease: A unifying hypothesis. Hypertension 2001; 37: 1047-1052. (Pubitemid 32304002)
19. Textor SC, Glockner JF, Lerman LO, et al,. The use of magnetic resonance to evaluate tissue oxygenation in renal artery stenosis. J Am Soc Nephrol 2008; 19: 780-788.
20. Mohini R,. Clinical efficacy of recombinant human erythropoietin in hemodialysis patients. Semin Nephrol 1989; 9: 16-21. (Pubitemid 19200764)